

---

# **Urologic Malignancies: Quality of Life Issues**

Guest Editors

E.A. Tanagho, San Francisco, Calif.

P.R. Carroll, San Francisco, Calif.

27 figures, 14 tables, 1991

**KARGER**

---

---

S. Karger · Medical and Scientific Publishers  
Basel · München · Paris · London · New York · New Delhi · Bangkok · Singapore · Tokyo · Sydney

---

#### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'Information for Readers and Subscribers').

© Copyright 1991 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
Printed in Switzerland on acid-free paper by  
Thür AG Offsetdruck, Pratteln  
ISBN 3-8055-5399-4

---

## Contents

<b>Introduction</b>	
Tanagho, E.A.; Carroll, P.R. . . . .	245
<b>Quality of Life: How Is It Measured and Defined?</b>	
Breslin, S. . . . .	246
<b>Pain Management for Urological Malignancies</b>	
McKay, W.R. . . . .	252
<b>Impotence after Radical Pelvic Surgery: Physiology and Management</b>	
Luc, T.F. . . . .	259
<b>Nerve Sparing and Continence Preservation during Radical Prostatec- tomy</b>	
Narayan, P. . . . .	266
<b>The Value of Screening for Prostatic Carcinoma: A Commentary</b>	
Hinman, F., Jr. . . . .	275
<b>Organ Preservation in the Management of Pelvic Rhabdomyosarcoma</b>	
Massad, C.A.; Kogan, B.A.; Ablin, A.R. . . . .	279
<b>Use of the Ileocecal Segment for Bladder Substitution or Continent Urinary Diversion</b>	
Carroll, P.R.; McAninch, J.W. . . . .	283
<b>Surveillance for Clinical Stage I Nonseminomatous Testis Carcinoma: Rationale and Results</b>	
Stephenson, R.A. . . . .	290
<b>Stage A Nonseminomatous Testis Carcinoma: Rationale and Results of Nerve-Sparing Retroperitoneal Lymphadenectomy</b>	
Foster, R.S.; Donohue, J.P.; Bihle, R. . . . .	294
<b>Assessment of Risk in Metastatic Testis Carcinoma: Impact on Treat- ment</b>	
Bajorin, F.; Geller, N.L.; Bosl, G.J. . . . .	298
<b>Use of Biological Response Modifiers for Management of Renal Cell Carcinoma</b>	
Wilkinson, M.; Aronson, F. . . . .	304